Annual report pursuant to Section 13 and 15(d)

RESEARCH AND DEVELOPMENT

v3.22.1
RESEARCH AND DEVELOPMENT
12 Months Ended
Dec. 31, 2021
Research and Development [Abstract]  
RESEARCH AND DEVELOPMENT

 

15. RESEARCH AND DEVELOPMENT

 

During the year ended December 31, 2021, the Company spent $474,338 (December 31, 2020 - $123,915) in research and development costs in relation to the development of a biosphere facility and product development in relation to the IP asset purchase from Manna Nutritional Group, LLC (see Note 7). The following represents the breakdown of research and development activities:

 

    December 31, 2021     December 31, 2020  
Architectural fees   $ -     $ 28,397  
Engineering consultants     -       16,962  
Design and construction     177,407       4,406  
Product development     296,931       74,150  
 Research and development costs   $ 474,338     $ 123,915  

 

The Company recorded Scientific Research and Experimental Development (“SR&ED”) tax incentive income of $Nil during the year ended December 31, 2021 (December 31, 2020 - $106,195). SR&ED tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The Company’s SR&ED tax incentive income has been recognized as other income as it is not indicative of the core operating activities or revenue producing goals of the Company.